Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pacira Pharmaceuticals (PCRX) PT Lowered to $66 at BMO Capital
August 5, 2021 12:41 PM EDTBMO Capital analyst Gary Nachman lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $66.00 (from $70.00) while maintaining a Market Perform rating.
The analyst commented, "Exparel had solid 2Q (preannounced 7/13), and PCRX is optimistic strong momentum should continue in 2H21 with... More
Pacira Pharma (PCRX) Tops Q2 EPS by 8c
August 3, 2021 8:08 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.77, $0.08 better than the analyst estimate of $0.69. Revenue for the quarter came in at $135.6 million versus the consensus estimate of $128.01 million.
Financial Guidance:
The companys net product sales were negatively impacted by the COVID-19 pandemic in 2020 due to the... More
